The present invention is directed to the combination therapy of DLBCL with a BET inhibitor, a Bcl-2 inhibitor and an anti-CD20 antibody.La présente invention concerne la polythérapie de DLBCL avec un inhibiteur BET, un inhibiteur Bcl -2 et un anticorps anti-CD20.